Publication Venue For
- BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. 2011
- A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. 2009
- Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. 2007
- Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial. 2007
- Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. 2006
- Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. 2005
- The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. 2003
- Camptothecin analogues with enhanced antitumor activity at acidic pH. 2000
- Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide. 2000
- Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. 1998